Clinical trials: Dupilumab
Asthma
Similarities and Differences of Biological Therapies for Severe Asthma.
This is an ambispective multicenter longitudinal observational study to evaluate the efficacy and safety profile of biological therapies in patients diagnosed with severe asthma in real life conditions.
- Trial name
- NCT04665141
- Testing
- Mepolizumab, Omalizumab, Reslizumab
- Where
- Spain
- Volunteers
- 600 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Chronic Obstructive Pulmonary Disease (COPD)
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
Study to evaluate the change of health-related quality of life, patient characteristics, efficacy and safety in Chronic Obstructive Pulmonary Disease (COPD) patients with Dupilumab therapy in a real-world setting over 24 months.
- Trial name
- ANEMO (NCT07052396)
- Testing
- Dupilumab
- Where
- 18 sites in Germany
- Volunteers
- 350 people
- Sponsor
- Sanofi
Chronic Spontaneous Urticaria
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
This was a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study was to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of…
- Trial name
- NCT05526521
- Testing
- Dupilumab
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 15 people
- Sponsor
- Sanofi
Atopic Dermatitis, Sleep Disturbance
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
- Trial name
- NCT05042258
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Asthma
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
- Trial name
- NCT04743791
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sally E. Wenzel MD
Atopic Dermatitis
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these…
- Trial name
- LEADS (NCT05436535)
- Testing
- Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide
- Where
- 10 sites in United States
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe.
- Trial name
- AIM4:Next Step (NCT06572228)
- Testing
- dupilumab, ICS/LABA
- Where
- 77 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Allergies Food Milk
Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy
This is a phase 2, multicenter, randomized, double-blind, parallel group, 2 arm study in approximately 40 subjects aged 4 to 50 years, inclusive, who are allergic to cow's milk.
- Trial name
- NCT04148352
- Testing
- Dupilumab
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Andrew J Long, PharmD
Asthma
Registry of Asthma Patients Initiating DUPIXENT®
The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life.
- Trial name
- RAPID (NCT04287621)
- Testing
- DUPIXENT®
- Where
- 128 sites in United States, Canada and 8 more
- Volunteers
- 718 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy
Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects
Primary Objective: To determine and compare the pharmacokinetic (PK) profiles of 2 different SAR231893 (REGN668) drug products after administration of a single subcutaneous (SC) dose Secondary Objective: To determine and compare…
- Trial name
- NCT01537640
- Testing
- SAR231893 (REGN668) DP1, SAR231893 (REGN668) DP2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as…
- Trial name
- DUPILAB (NCT06169527)
- Testing
- Dupilumab
- Where
- 42 sites in France
- Volunteers
- 303 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Level Up (NCT05601882)
- Testing
- Dupilumab, Upadacitinib
- Where
- 257 sites in United States, Australia and 27 more
- Volunteers
- 920 people
- Sponsor
- AbbVie
Atopic Dermatitis
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
This is an open-label, single-sequence DDI study designed to examine the effects of dupilumab on the pharmacokinetics of selected cytochrome P450 substrates in adult patients with moderate to severe AD.
- Trial name
- NCT02647086
- Testing
- Dupilumab, Midazolam, Omeprazole
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Regeneron Pharmaceuticals
Neterton Syndrome
Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab
In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome.
- Trial name
- NCT07151508
- Testing
- Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab for Prevention of Recurrence of CRSwNP After ESS
The investigators believe that administering Dupilumab during the pre- and peri-operative period of surgery for chronic rhinosinusitis with nasal polyps (CRSwNP) will safely downregulate Type 2 inflammation of the healing sinus…
- Trial name
- NCT04596189
- Testing
- Dupilumab 300 MG in 2 ML Prefilled Syringe, Mometasone Furoate nasal spray
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Atopic Dermatitis
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of…
- Trial name
- NCT05527964
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Sanofi
Rhinosinusitis Chronic, Nasal Polyps
BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry
With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life.
- Trial name
- BIOPOSE2 (NCT06501807)
- Testing
- Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).
- Where
- 2 sites in France
- Volunteers
- 900 people
- Sponsor
- University Hospital, Lille
Atopic Dermatitis
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China
This is a 32-week, open-label, exploratory study with a 4-week screening period, 16-week treatment phase designed to investigate dupilumab's effect on skin barrier function as measured by TEWL before and after STS in…
- Trial name
- PELISTAD CN (NCT05680298)
- Testing
- Dupilumab
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dermatitis, Atopic
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).
- Trial name
- SOLO 2 (NCT02277769)
- Testing
- Dupilumab
- Where
- 93 sites in United States, Canada and 9 more
- Volunteers
- 708 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: To assess the long-term efficacy of dupilumab in pediatric…
- Trial name
- NCT02612454
- Testing
- Dupilumab
- Where
- 84 sites in United States, Canada and 5 more
- Volunteers
- 880 people
- Sponsor
- Regeneron Pharmaceuticals